Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2042937 | 0.90 | CA2 (0.34) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL20001450 | 0.90 | CA1 (0.31) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL15463273 | 0.84 | CA1 (0.30) | CA12CA1CA2CA9TGFBR1 | |
| SCHEMBL25009830 | 0.83 | CCNA2 (0.31) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL11044 | 0.81 | — | — | |
| SCHEMBL10457 | 0.81 | — | — | |
| SCHEMBL11899084 | 0.79 | SLC6A2 (0.59) | — | |
| SCHEMBL23735054 | 0.79 | EPHX2 (0.35) | CCNA2CDK2CCNA1CDK5CDK5R1 | |
| SCHEMBL5951 | 0.78 | — | — | |
| SCHEMBL12986271 | 0.78 | TGFBR1 (0.35) | CCNA2CDK2CCNA1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP BIOSCIENCES CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | PEPD, NRDC, DPP4 | CCNA2 4684/4885CDK2 4346/4885CCNA1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.